Initiator Pharma A/S
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor, which completed phase IIb clinical trial primarily targeting the dopamine system for treatment resistant organic erectile dysfunction, as well as completed phase I to t… Read more
Initiator Pharma A/S (INIT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.144x
Based on the latest financial reports, Initiator Pharma A/S (INIT) has a cash flow conversion efficiency ratio of -0.144x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-4.68 Million) by net assets (Skr32.47 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Initiator Pharma A/S - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Initiator Pharma A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Initiator Pharma A/S Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Initiator Pharma A/S ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Medicus Pharma Ltd. Common Stock
OTCBB:MDCX
|
8.396x |
|
Cadrenal Therapeutics, Inc. Common Stock
NASDAQ:CVKD
|
-0.862x |
|
Electromagnetica SA
RO:ELMA
|
0.031x |
|
Seojin Automotive Co.Ltd
KQ:122690
|
-0.029x |
|
Akobo Minerals AB (publ)
OL:AKOBO
|
0.133x |
|
The INX Digital Company Inc.
OTCQB:INXDF
|
-0.333x |
|
Galena Mining Ltd
AU:G1A
|
-0.086x |
|
IL&FS Investment Managers Limited
NSE:IVC
|
-0.035x |
Annual Cash Flow Conversion Efficiency for Initiator Pharma A/S (2016–2024)
The table below shows the annual cash flow conversion efficiency of Initiator Pharma A/S from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr14.78 Million | Skr-12.08 Million | -0.817x | +48.31% |
| 2023-12-31 | Skr11.16 Million | Skr-17.65 Million | -1.581x | -64.49% |
| 2022-12-31 | Skr34.02 Million | Skr-32.70 Million | -0.961x | +1.36% |
| 2021-12-31 | Skr34.99 Million | Skr-34.10 Million | -0.974x | -74.10% |
| 2020-12-31 | Skr14.41 Million | Skr-8.06 Million | -0.560x | +35.17% |
| 2019-12-31 | Skr9.91 Million | Skr-8.55 Million | -0.863x | -5.32% |
| 2018-12-31 | Skr16.57 Million | Skr-13.58 Million | -0.820x | +37.20% |
| 2017-12-31 | Skr5.96 Million | Skr-7.78 Million | -1.305x | -372.03% |
| 2016-12-31 | Skr-371.00K | Skr-178.00K | 0.480x | -- |